ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.

Article Details

Citation
Copy to clipboard

Takakuwa O, Oguri T, Uemura T, Kunii E, Nakao M, Hijikata H, Kawaguchi Y, Ohkubo H, Takemura M, Maeno K, Niimi A

ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.

Anticancer Res. 2014 Jul;34(7):3517-22.

PubMed ID
24982363 [ View in PubMed
]
Abstract

BACKGROUND: Amrubicin is a promising therapy for lung cancer, but is associated with a high incidence of severe neutropenia. The present study assessed the utility of ABCB1 and NAD(P)H quinone oxidoreductase 1 (NQO1) polymorphism as a predictor of amrubicin-induced neutropenia. MATERIALS AND METHODS: Fifty-four Japanese lung cancer patients who received amrubicin chemotherapy were consecutively recruited and toxicities and SNPs (MDR1; C1236T, C3435T and G2677T/A, NQO1; C609T) were evaluated. RESULTS: The incidence of neutropenia was higher in patients treated with 40 mg/m2 of amrubicin (n=32) compared to patients treated with 35 mg/m2 of amrubicin (n=22) (53.1% vs. 22.7%). Patients who were homogenous for the wild-type allele of C3435T were at significantly higher risk of neutropenia compared to patients with other genotypes. By contrast, the C609T genotype of NQO1 was not related to neutropenia. CONCLUSION: C3435T polymorphisms of ABCB1 might be able to predict severe amrubicin-induced neutropenia.

DrugBank Data that Cites this Article

Drugs